Journal
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
Volume 65, Issue 12, Pages 1423-1432Publisher
ASSOC MEDICA BRASILEIRA
DOI: 10.1590/1806-9282.65.12.1423
Keywords
-
Categories
Ask authors/readers for more resources
Lung cancer is the worldwide leading cause of cancer-related deaths in both genders. Pembrolizumab is a IgG4 monoclonal antibody, which is highly selective, humanized, and binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with the PD-L1and PD-L2 ligands. We conducted a systematic review of the literature, without time restrictions, in the Medline database, using the following PICO: Adult patients with advanced NSCLC; Treatment with pembrolizumab alone or associated with chemotherapy, compared with chemotherapy, except for monochemotherapy with docetaxel and death outcomes (due to any cause) and adverse events. We selected 244 papers to answer the clinical question. The details of the methodology and the results of this guideline are set out in Annex 1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available